Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 3: Pharmacoeconomics in Oncology: Direct and Indirect Costs
Submit an article Journal homepage
391
Views
7
CrossRef citations to date
0
Altmetric
Original research

Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years

Sungju Kima Healthcare Group, Lee&Ko, Seoul, Republic of Korea
,
Jinhong Kimb Department of Market Access, GlaxoSmithKline Korea, Seoul, Republic of Korea
,
Hyunyoung Choc Department of Market Access, AbbVie Korea, Seoul, Republic of Korea
,
Kyungmin Leed Department of Patient Access and Public Affairs, Novartis Korea, Seoul, Republic of Korea
,
Chiyoung Ryue Department of Healthcare Policy and Market Access, Korea Research-based Pharma Industry Association, Seoul, Republic of Korea
&
Jong Hyuk Leef Department of Pharmaceutical Engineering, Hoseo University, Asan, Republic of KoreaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9932-8879
ORCID Icon
Pages 479-488 | Received 18 Oct 2020, Accepted 02 Dec 2020, Published online: 17 Dec 2020

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Joon Seok Bang & Jong Hyuk Lee. (2021) The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways. Expert Opinion on Orphan Drugs 9:4, pages 105-112.
Read now

Articles from other publishers (6)

Hongbin Yi, Fenghao Shi, Zihao Wang, Liping Kuai, Dongyan Xu, Yu Xie & Hua Xing. (2023) Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis. BMJ Open 13:10, pages e064811.
Crossref
Sungju Kim, Ji Yeon Lee, Seong Ha Cho, Eileen J. Shin, Minyoung Kim & Jong Hyuk Lee. (2023) An Industry Survey on Unmet Needs in South Korea’s New Drug Listing System. Therapeutic Innovation & Regulatory Science 57:4, pages 759-768.
Crossref
Hyungmin Kim, Brian Godman, Hye-Young Kwon & Song Hee Hong. (2023) Introduction of managed entry agreements in Korea: Problem, policy, and politics. Frontiers in Pharmacology 14.
Crossref
SungKyung Lee & Jong Hyuk Lee. (2023) Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU. Frontiers in Public Health 11.
Crossref
Yichen Zhang, Haishaerjiang Wushouer, Sheng Han, Mengyuan Fu, Xiaodong Guan, Luwen Shi & Anita Wagner. (2021) The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. BMJ Global Health 6:7, pages e006196.
Crossref
Jong Hyuk Lee. (2021) Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison. Healthcare 9:3, pages 296.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.